Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL — Sponsor Intelligence | 14 EU Trials

Filter these 14 trials by condition, phase, country and more.

Open in Search →

14 Registered trials

3 Recruiting

7 Completed trials

1 Countries active

26 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase III: 2 Phase II/III: 1 Phase II: 5 Phase I/II: 1 Phase III/IV: 1 Phase IV: 4

100%

7 of 7 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Germ cell cancer 1 Niemann-Pick disease 1

Top IMPs

All trials

14 total

A phase 2, Multicenter Study of TILs Treatment in Germ Cell tumors: the ARES Study Pending

2025-522427-10-00 Phase II 1 country AUTOLOGOUS TUMOUR-INFILTRATING LYMPHOCYTES
STUDY TO FIND OUT WHETHER A SHORTER ANTIBIOTIC TREATMENT (7 DAYS) IS AS EFFECTIVE AND SAFE AS THE USUAL ONE (14 DAYS) IN PATIENTS WITH AN IN… Pending

2025-523120-53-00 Phase III/IV 1 country
Mechanisms of Resistance to anti-PD-1 Therapy in cutaneous Squamous Cell Carcinomas: Impact of Tumor Cell Plasticity on Promoting Myeloid Su… Pending

2025-524255-32-00 Phase II 1 country CEMIPLIMAB
Study evaluating the efficacy and safety of daridorexant in patients with major depressive disorder and insomnia. Pending

2025-524794-16-00 Phase IV 1 country
Efficacy and tolerability of efgartigimod as early treatment in patients with generalized myasthenia gravis. Recruiting

2024-516015-24-00 Phase IV 1 country EFGARTIGIMOD ALFA
GLP-1 receptor agonists as preventive treatment of diabetes after renal transplantation: randomized clinical trial. Study 1: Immediate Kidne… Recruiting

2023-506437-29-00 Phase III 1 country DULAGLUTIDE
A Non-Randomized, Open-Label Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive … Recruiting

2024-515228-36-00 Phase IV 1 country HUMAN PAPILLOMAVIRUS TYPE 31 L1 PROTEIN - ADSORBED - IN THE FORM OF VIRUS-LIKE P…
OPEN-LABEL EXTENSION STUDY TO ASSESS THE SAFETY AND LONG-TERM EFFECTIVENESS OF ORALLY ADMINISTERED EFAVIRENZ IN PATIENTS DIAGNOSED WITH ADUL… Ended

2023-505832-36-01 Phase II 1 country
A phase 2, Multicenter Study of TILs Treatment in Advanced Tumors with Alterations in the SWI/SNF Complex: the TILTS Study Ended

2023-504632-17-00 Phase II 1 country ALDESLEUKIN; AUTOLOGOUS TUMOUR-INFILTRATING LYMPHOCYTES; CYCLOPHOSPHAMIDE MONOHY…
Effect of dimethyl fumarate administered to patients with adrenomyeloneuropathy: a multicenter, placebo controlled, phase IIb/III trial Ended

2023-506795-27-00 Phase II/III 1 country DIMETHYL FUMARATE
Comparison of three short rifamycin-based regimens to treat latent tuberculosis in patients with end-stage kidney disease. Ended

2023-506432-32-00 Phase IV 1 country ISONIAZID, PYRIDOXINE; RIFAMPICIN
GLP-1 receptor agonists as preventive treatment of diabetes after renal transplantation: a single-arm interventional clinical trial. Study 2… Ended

2023-506436-33-00 Phase III 1 country DULAGLUTIDE
Phase-II randomized clinical trial to evaluate the effect of Loratadine associated with Rapamune on Lymphagioleiomyomatosis (LAM). Ended

2024-516808-42-00 Phase II 1 country LORATADINE
Phase I/II stUdy of ALoCelyvir in patientS with mEtastaticUveal Melanoma (PULSE-UM) Ended

2024-515032-76-00 Phase I/II 1 country ALLOGENIC BONE MARROW-DERIVED MESENCHYMAL STEM CELLS TRANSDUCED WITH ICOVIR-5, E…

Showing 1–14 of 14 trials

← All sponsors A–Z